COMPANY UPDATES
09
Sep
2019
Two new Pfizer-coauthored studies validate Novoheart’s pioneering human bioengineered heart tissues and chambers for improving drug development

Two new Pfizer-coauthored studies validate Novoheart’s pioneering human bioengineered heart tissues and chambers for improving drug development

04
Sep
2019
Novoheart Holdings Inc. Reports Fourth Quarter and Fiscal 2019 Financial Results

Novoheart Holdings Inc. reports financial results for the three and twelve months ended June 30, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards (IFRS).

28
Jun
2019
Novoheart Holdings Inc. Completes Acquisition of Xellera Therapeutics

Novoheart is pleased to announce that it has completed its previously announced acquisition of all of the shares of Xellera Therapeutics Limited.

17
Jun
2019
Novoheart Announces Appointment of New Chief Financial Officer

Novoheart is pleased to announce the appointment of Joseph Leung as its new Chief Financial Officer and Corporate Secretary. Joseph will be replacing Dr. Camie Chan, who has been serving as the Company's interim CFO and Corporate Secretary.

Subscribe To Our Newsletter

Fill out the following to subscribe and start receiving updates from us!